AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03111927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula: standard level of myelin-relevant nutrients
Description: Feeding with the assigned infant formula begun as soon as the child was enrolled in the study (from 2 weeks up to 5 weeks of life) and lasted up to 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day depended upon age, weight, and appetite. The product was given daily ad libitum to the child from enrollment up to 12 months.
Study NCT02602301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
Study NCT02602301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: different oxytocin diluents and effect on fetal bilirubin\&sodium levels.
Study NCT01040104 — intervention group
Intervention type: OTHER
Intervention: Skin sample
Description: Taken from regularly discarded tissue during routine operation
Study NCT01040104 — intervention group
Intervention type: OTHER
Intervention: Skin biopsy
Description: Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
Study NCT01040104 — intervention group
Intervention type: OTHER
Intervention: Skin biopsy
Description: Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
Study NCT01040104 — intervention group
Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 0
Study NCT03442751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Article A
Description: Riboflavin Ophthalmic Solution A
Study NCT03442751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Article B
Description: Riboflavin Ophthalmic Solution B
Study NCT03442751 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo Vehicle of Test Article
Study NCT03442751 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: KXL medical device system
Description: Mock UVA light source
Study NCT03442751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KXL medical device system
Description: Cross-linking UVA light source
Study NCT02174263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: Given IV
Study NCT02174263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02174263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00516841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volociximab
Description: 15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
Study NCT01860365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary medicine consultation and treatment
Description: Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
Study NCT01860365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients receiving conventional supportive care
Description: Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
Study NCT01912092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Askina Calgitrol paste
Study NCT00774163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
Study NCT00774163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
Study NCT02945241 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: Intravenous
Study NCT02945241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Intravenous
Study NCT02945241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cystatin C dosing algorithm
Description: Expressed in milliliters per minute
Study NCT02945241 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Creatine clearance dosing algorithm
Description: Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
Study NCT04656756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Care
Description: A clinical and standardized workflow was created for both experimental and control groups. This standardized workflow: consisted of services which included the management of basic medications, routine care regarding the postpartum period, newborn care and health education. After the standardized clinic workflow was formed, a personalized care plan was developed for the experimental group. Each care procedure was shared with the participants in the experimental group. Moreover, all potential alternative care plans were presented to the participants.
Study NCT00855894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
Study NCT00855894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andrographolid Sulfonate Injection (AS Injection)
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cephalosporin
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporin
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin, Minocycline or Doxycycline
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin, Minocycline or Doxycycline
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-clavulantic acid
Study NCT01520766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prefabricated titanium post
Description: posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
Study NCT01520766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prefabricated glass fiber reinforced composite post
Description: posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
Study NCT00533884 — intervention group
Intervention type: OTHER
Intervention: Assessment of therapy complications
Description: Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
Study NCT00533884 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive assessment
Description: Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
Study NCT00533884 — intervention group
Intervention type: OTHER
Intervention: Quality-of-life assessment
Description: Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
Study NCT01246986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulantic acid
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoroquinolones
Study NCT02843698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT02164578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Study NCT02913118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00780377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bradykinin
Description: Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
Study NCT00776035 — intervention group
Intervention type: PROCEDURE
Intervention: PET (Positron Emission Tomography)
Description: This is a diagnostic scan that requires the injection of radioactive tracer compounds intravenously using an IV placed in the arm.
Study NCT00776035 — intervention group
Intervention type: PROCEDURE
Intervention: Echocardiogram
Description: An echocardiogram is an ultrasound of the heart. Participants received a complete 2D- and Doppler echocardiographic examination on the day of the PET scan.
Study NCT00776035 — intervention group
Intervention type: RADIATION
Intervention: ^15O-water
Description: This is a radioactive tracer used to study blood flow in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
Study NCT00776035 — intervention group
Intervention type: RADIATION
Intervention: 1-^11C-palmitate
Description: This is a radioactive tracer used to study fatty acid usage in the heart during the PET scan. It was administered intravenously at a dose of 20 mCi.
Study NCT00776035 — intervention group
Intervention type: RADIATION
Intervention: 1-^11C-glucose
Description: This is a radioactive tracer used to study glucose usage in the heart during the PET scan. It was administered intravenously at a dose of 20 Mci..
Study NCT02164578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT03521076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
Study NCT01901458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia® IDL-Set
Description: Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
Study NCT01901458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectra Optia® Collection Set
Description: Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
Study NCT03662802 — intervention group
Intervention type: OTHER
Intervention: Neural Network Classifier
Description: The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
Study NCT03045211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Standing Table
Description: The dynamic standing table is a height-adjustable standing table which gives periodic cues to the user to make stepping movements.
Study NCT02094274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS40468
Study NCT02094274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone propionate
Study NCT01246986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Administered orally
Study NCT01246986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study NCT02094274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04021238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study NCT01040104 — intervention group
Intervention type: OTHER
Intervention: Blood taking
Description: Blood taking on day 90
Study NCT04021238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid microspheres
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study NCT01387087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study NCT03724916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneous injection.
Study NCT03724916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-079 Placebo
Description: TAK-079 placebo-matching subcutaneous injection.
Study NCT01284816 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bariatric surgery
Description: The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
Study NCT01897558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker implantation
Study NCT01834573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical exercise
Description: 10 weeks physical exercise; three times a week
Study NCT03666546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose crystals 20 g
Description: White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
Study NCT03666546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose crystals 30 g
Description: White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT03666546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose liquid 20 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT03666546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose liquid 30 g
Description: Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT03666546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
Study NCT03666546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Still water
Description: 250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
Study NCT01835470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Study NCT00297492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction Phone Counseling
Description: Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
Study NCT00297492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abrupt Phone Counseling
Description: Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
Study NCT00297492 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Abrupt Phone Counseling
Description: Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
Study NCT00297492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-Quit Nicotine Lozenges
Description: 2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke.
Study NCT00297492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post-Quit Nicotine Lozenges
Description: 2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke.
Study NCT00297492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Quit Nicotine Lozenges
Description: 2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke.
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS0421a
Description: treatment will be given for 3 days
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAS0421a
Description: treatment will be given for 3 days
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS0421b
Description: treatment will be given for 3 days
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAS0421b
Description: treatment will be given for 3 days
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAS0421c
Description: treatment will be given for 3 days
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAS0421c
Description: treatment will be given for 3 days
Study NCT03892772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be given for 3 days
Study NCT02026700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bariederm cream
Description: patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
Study NCT03861598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.